Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1
Background and Aims: Tongxinluo (TXL) is a multifunctional traditional Chinese medicine that has been widely used to treat cardiovascular and cerebrovascular diseases. However, no studies have explored whether TXL can protect human cardiomyocytes (HCMs) from ischemia/reperfusion (I/R) injury. Reperf...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00775/full |
id |
doaj-aaf9aa2d42074d74bb582eff31815059 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gui-hao Chen Chuan-sheng Xu Jie Zhang Qing Li He-he Cui Xiang-dong Li Li-ping Chang Rui-jie Tang Jun-yan Xu Xia-qiu Tian Pei-sen Huang Jun Xu Chen Jin Yue-jin Yang |
spellingShingle |
Gui-hao Chen Chuan-sheng Xu Jie Zhang Qing Li He-he Cui Xiang-dong Li Li-ping Chang Rui-jie Tang Jun-yan Xu Xia-qiu Tian Pei-sen Huang Jun Xu Chen Jin Yue-jin Yang Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1 Frontiers in Pharmacology myocardial reperfusion injury cardioprotection tongxinluo human cardiomyocytes apoptosis p70s6k1 |
author_facet |
Gui-hao Chen Chuan-sheng Xu Jie Zhang Qing Li He-he Cui Xiang-dong Li Li-ping Chang Rui-jie Tang Jun-yan Xu Xia-qiu Tian Pei-sen Huang Jun Xu Chen Jin Yue-jin Yang |
author_sort |
Gui-hao Chen |
title |
Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1 |
title_short |
Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1 |
title_full |
Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1 |
title_fullStr |
Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1 |
title_full_unstemmed |
Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1 |
title_sort |
inhibition of mir-128-3p by tongxinluo protects human cardiomyocytes from ischemia/reperfusion injury via upregulation of p70s6k1/p-p70s6k1 |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2017-10-01 |
description |
Background and Aims: Tongxinluo (TXL) is a multifunctional traditional Chinese medicine that has been widely used to treat cardiovascular and cerebrovascular diseases. However, no studies have explored whether TXL can protect human cardiomyocytes (HCMs) from ischemia/reperfusion (I/R) injury. Reperfusion Injury Salvage Kinase (RISK) pathway activation was previously demonstrated to protect the hearts against I/R injury and it is generally activated via Akt or (and) Erk 1/2, and their common downstream protein, ribosomal protein S6 kinase (p70s6k). In addition, prior studies proved that TXL treatment of cells promoted secretion of VEGF, which could be stimulated by the increased phosphorylation of one p70s6k subtype, p70s6k1. Consequently, we hypothesized TXL could protect HCMs from I/R injury by activating p70s6k1 and investigated the underlying mechanism.Methods and Results: HCMs were exposed to hypoxia (18 h) and reoxygenation (2 h) (H/R), with or without TXL pretreatment. H/R reduced mitochondrial membrane potential, increased bax/bcl-2 ratios and cytochrome C levels and induced HCM apoptosis. TXL preconditioning reversed these H/R-induced changes in a dose-dependent manner and was most effective at 400 μg/mL. The anti-apoptotic effect of TXL was abrogated by rapamycin, an inhibitor of p70s6k. However, inhibitors of Erk1/2 (U0126) or Akt (LY294002) failed to inhibit the protective effect of TXL. TXL increased p70s6k1 expression and, thus, enhanced its phosphorylation. Furthermore, transfection of cardiomyocytes with siRNA to p70s6k1 abolished the protective effects of TXL. Among the micro-RNAs (miR-145-5p, miR-128-3p and miR-497-5p) previously reported to target p70s6k1, TXL downregulated miR-128-3p in HCMs during H/R, but had no effects on miR-145-5p and miR-497-5p. An in vivo study confirmed the role of the p70s6k1 pathway in the infarct-sparing effect of TXL, demonstrating that TXL decreased miR-128-3p levels in the rat myocardium during I/R. Transfection of HCMs with a hsa-miR-128-3p mimic eliminated the protective effects of TXL.Conclusions: The miR-128-3p/p70s6k1 signaling pathway is involved in protection by TXL against HCM apoptosis during H/R. Overexpression of p70s6k1 is, therefore, a potential new strategy for alleviating myocardial reperfusion injury. |
topic |
myocardial reperfusion injury cardioprotection tongxinluo human cardiomyocytes apoptosis p70s6k1 |
url |
http://journal.frontiersin.org/article/10.3389/fphar.2017.00775/full |
work_keys_str_mv |
AT guihaochen inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT chuanshengxu inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT jiezhang inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT qingli inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT hehecui inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT xiangdongli inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT lipingchang inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT ruijietang inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT junyanxu inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT xiaqiutian inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT peisenhuang inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT junxu inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT chenjin inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 AT yuejinyang inhibitionofmir1283pbytongxinluoprotectshumancardiomyocytesfromischemiareperfusioninjuryviaupregulationofp70s6k1pp70s6k1 |
_version_ |
1725709958991839232 |
spelling |
doaj-aaf9aa2d42074d74bb582eff318150592020-11-24T22:39:15ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122017-10-01810.3389/fphar.2017.00775297539Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1Gui-hao Chen0Chuan-sheng Xu1Jie Zhang2Qing Li3He-he Cui4Xiang-dong Li5Li-ping Chang6Rui-jie Tang7Jun-yan Xu8Xia-qiu Tian9Pei-sen Huang10Jun Xu11Chen Jin12Yue-jin Yang13State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Cardiac Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Surgical Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBackground and Aims: Tongxinluo (TXL) is a multifunctional traditional Chinese medicine that has been widely used to treat cardiovascular and cerebrovascular diseases. However, no studies have explored whether TXL can protect human cardiomyocytes (HCMs) from ischemia/reperfusion (I/R) injury. Reperfusion Injury Salvage Kinase (RISK) pathway activation was previously demonstrated to protect the hearts against I/R injury and it is generally activated via Akt or (and) Erk 1/2, and their common downstream protein, ribosomal protein S6 kinase (p70s6k). In addition, prior studies proved that TXL treatment of cells promoted secretion of VEGF, which could be stimulated by the increased phosphorylation of one p70s6k subtype, p70s6k1. Consequently, we hypothesized TXL could protect HCMs from I/R injury by activating p70s6k1 and investigated the underlying mechanism.Methods and Results: HCMs were exposed to hypoxia (18 h) and reoxygenation (2 h) (H/R), with or without TXL pretreatment. H/R reduced mitochondrial membrane potential, increased bax/bcl-2 ratios and cytochrome C levels and induced HCM apoptosis. TXL preconditioning reversed these H/R-induced changes in a dose-dependent manner and was most effective at 400 μg/mL. The anti-apoptotic effect of TXL was abrogated by rapamycin, an inhibitor of p70s6k. However, inhibitors of Erk1/2 (U0126) or Akt (LY294002) failed to inhibit the protective effect of TXL. TXL increased p70s6k1 expression and, thus, enhanced its phosphorylation. Furthermore, transfection of cardiomyocytes with siRNA to p70s6k1 abolished the protective effects of TXL. Among the micro-RNAs (miR-145-5p, miR-128-3p and miR-497-5p) previously reported to target p70s6k1, TXL downregulated miR-128-3p in HCMs during H/R, but had no effects on miR-145-5p and miR-497-5p. An in vivo study confirmed the role of the p70s6k1 pathway in the infarct-sparing effect of TXL, demonstrating that TXL decreased miR-128-3p levels in the rat myocardium during I/R. Transfection of HCMs with a hsa-miR-128-3p mimic eliminated the protective effects of TXL.Conclusions: The miR-128-3p/p70s6k1 signaling pathway is involved in protection by TXL against HCM apoptosis during H/R. Overexpression of p70s6k1 is, therefore, a potential new strategy for alleviating myocardial reperfusion injury.http://journal.frontiersin.org/article/10.3389/fphar.2017.00775/fullmyocardial reperfusion injurycardioprotectiontongxinluohuman cardiomyocytesapoptosisp70s6k1 |